Impact Factor
3.95
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.31
946 total citations
h5-index
38
h5 depth signal
Cited share
87.1%
162 of 186
Total citations
946
Citation footprint
Metric signal
4.58
External metric anchor
Self-citation
0.1%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
310
China
124
Italy
123
United Kingdom
59
India
58
Citing Fields of Research
Immunology
178
Oncology
141
Cancer & Development
134
Cancer, Autophagy & Apoptosis
117
Neurodegenerative Disorders
103
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,801
Articles tracked across the journal lifetime
Indexed publication set
186
162 cited publications
Last 12 months
101
9.2 publications/month
Open access share
20.8%
21 OA publications in the last year
Leading citing country
United States
310 citing publications
Leading citing field
Immunology
178 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v6n1, 2002-
v6n1, 2002-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Cancer, Autophagy & Apoptosis
Cancer & Development
Noncoding RNA
Neurodegenerative Disorders
Broad Categories
Therapeutics
Cancer, Autophagy & Apoptosis
Immunotherapy
Physiology
Immunology
Musculoskeletal Disorders
Noncoding RNA
Hematology
MeSH Descriptors
Drug Delivery Systems
Drug Design
Drug Therapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/14728222.2026.2738185
Open DOI
PTK7-targeted cancer therapies: molecular understanding and clinical developments
02
DOI 10.1080/14728222.2026.2748747
Open DOI
Targeting the microbiota-gut-brain axis in Alzheimer’s and Parkinson´s disease: recent therapeutic approaches
03
DOI 10.1080/14728222.2026.2748740
Open DOI
Molecular basis for developing tumor-targeted siRNAs for future immunotherapy
04
DOI 10.1080/14728222.2026.2747520
Open DOI
Overcoming adaptive resistance to cancer immunotherapy: molecular targeting strategies for the tumor microenvironment
05
DOI 10.1080/14728222.2026.2747518
Open DOI
Targeting protein misfolding and aggregation in neurodegenerative diseases: challenges for the identification and validation of targets for small molecules
1. Neurodegenerative diseases associated with pathological protein misfolding and aggregation are classified as proteinopathies, including subtypes such as synucleinopathies and tauopathies defined...
06
DOI 10.1080/14728222.2026.2747529
Open DOI
New and emerging therapeutics and molecular targets for attention-deficit hyperactivity disorder
07
DOI 10.1080/14728222.2026.2747525
Open DOI
VAV1 targeting for cancer therapeutics: mechanistic understanding and preclinical promise
1. Guanine nucleotide exchange factors (GEFs) for the Rho family of small GTP-binding proteins catalyze the nucleotide exchange of GDP for GTP, thereby allowing Rho family proteins to engage downst...
08
DOI 10.1080/14728222.2026.2738346
Open DOI
Targeting the LOX-1 scavenger receptor for therapeutics and diagnostics
09
10
DOI 10.1080/14728222.2026.2738343
Open DOI
Extracellular vesicles redefine immune modulation through Toll-like receptor networks
Extracellular vesicles (EVs) are potent immunomodulators that can promote the transition from pro-inflammatory to regulatory immune responses across diverse pathological conditions. Tissue injury increases the release of damage- and path...
Bibliographical & Catalog Notes
Title from caption.
Also issued online.